Primary open angle glaucoma Ocular hypertension
Conditions
Interventions
None listed
Sponsors
Department of Ophthalmology, The University of Tokyo
Hara Eye Hospital Omiya hamada Eye Clinic Yotsuya Shirato Ophthalmology Clinic Eye Rose Clinic Yoshikawa Eye Clinic Ohkubo Eye Clinic Muramatsu Clinic Grace Eye Clinic Minami-Matsuyama Hospital Asato Eye Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with primary open-angle glaucoma (POAG) or ocular hypertension 2. Written informed consent 3. Male or female outpatient, 20 years of age or older 4. Patients treated with the same PG analogs or PG/b combination for 90 days or longer 5. Baseline IOP >= 13 mmHg 6. Corneal thickness: 450-580 micro meter 7. Required Ailamide administration for further IOP-lowering treatment
Exclusion criteria
Exclusion criteria: 1. Use of other IOP lowering drug or corticosteroid within past 90 days 2. History of surgical treatment for glaucoma 3. History of intraocular surgery within past 90 days 4. Treatment of a triamcinolone acetonide within past 180 days 5. Presence of any active retinal disease which may progress 6. Presence of any active ocular disease other than POAG or ocular hypertension 7. Presence of a serious systemic disease 8. Presence of corneal abnormality which is considered to preclude accurate measurement of IOP by Goldmann applanation tonometer 9. History of corneal transplantation or keratorefractive surgery 10. Decided to be inappropriate for this study by a physician in charge accurate measurement of IOP by Goldmann applanation tonometer 9. History of corneal transplantation or keratorefractive surgery 10. Decided to be inappropriate for this study by a physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IOP change from baseline at 12 weeks of additional administration of Ailamide | — |
Countries
Japan
Contacts
Public ContactAihara Makoto
The University of Tokyo Department of ophthalmology
Outcome results
None listed